KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma

被引：0

作者：

Ascierto, P. A. ^{[1
]}

Ferrucci, P. F. ^{[2
]}

Stephens, R. ^{[3
]}

Del Vecchio, M. ^{[4
]}

Atkinson, V. ^{[5
]}

Schmidt, H. ^{[6
]}

Schachter, J. ^{[7
]}

Queirolo, P. ^{[8
]}

Long, G. V. ^{[9
]}

Di Giacomo, A. M. ^{[10
]}

Svane, I. ^{[11
]}

Lotem, M. ^{[12
]}

Bar-Sela, G. ^{[13
]}

Couture, F. ^{[14
]}

Mookerjee, B. P. ^{[15
]}

Ghori, R. ^{[16
]}

Ibrahim, N. ^{[16
]}

Moreno, B. Homet ^{[16
]}

Ribas, A. ^{[17
]}

机构：

[1] Ist Nazl Tumori Fdn G Pascale, Melanoma Canc Immunotherapy & Dev Therapeut Unit, Naples, Italy

[2] Ist Europeo Oncol, Oncol, Milan, Italy

[3] Auckland City Hosp, Med Oncol, Auckland, New Zealand

[4] Fdn IRCCS Ist Nazl Tumori, Med Oncol, Milan, Italy

[5] Greenslopes Private Hosp, Gallipoli Med Res Fdn, Med Oncol, Brisbane, Qld, Australia

[6] Aarhus Univ Hosp, Oncol, Aarhus, Denmark

[7] Sheba Med Ctr Tel HaShomer, Ctr Canc, Inst Oncol, Oncol,Ella Lemelbaum Inst Melanoma, Ramat Gan, Israel

[8] IRCCS San Martino IST, Oncol Med, Genoa, Italy

[9] Univ Sydney, Melanoma Inst Australia, Med Oncol, Sydney, NSW, Australia

[10] Univ Hosp Siena, Ctr Immunooncol, Med Oncol, Siena, Italy

[11] Univ Copenhagen, Herlev Hosp, Oncol, Herlev, Denmark

[12] Hadassah Hebrew Med Ctr, Sharett Inst Oncol, Med Oncol, Jerusalem, Israel

[13] Rambam Hlth Care Campus, Oncol, Haifa, Israel

[14] Laval Univ, Ctr Hosp Univ Quebec Res Ctr, Hematol, Quebec City, PQ, Canada

[15] Novartis, Oncol Clin Dev, E Hanover, NJ USA

[16] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA

[17] Ronald Reagan UCLA Med Ctr, Med Oncol, Los Angeles, CA USA

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1244O

引用

页码：442 / 442

页数：1

共 50 条

[31] An open-label phase 2a study of combination dabrafenib (D) and trametinib (T) in Asian patients (pts) with advanced BRAF V600-mutant acral lentiginous melanoma (ALM) or cutaneous melanoma (CM)
Guo, J.
Chang, W-C.
Dechaphunkul, A.
Fan, Y.
Kim, T. M.
Lin, C-C.
Maneechavakajorn, J.
Shin, S. J.
Song, X.
Cheng, S-T.
Thongprasert, S.
Wong, C. S.
Wu, D.
Zhang, X.
Bettinger, S.
Zhang, P.
Mookerjee, B.
ANNALS OF ONCOLOGY, 2016, 27
[32] Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial
Nathan, P.
Dummer, R.
Long, G. V.
Ascierto, P. A.
Tawbi, H. A.
Robert, C.
Rutkowski, P.
Leonov, O.
Dutriaux, C.
Mandala', M.
Lorigan, P.
Ferrucci, P. F.
Flaherty, K. T.
Brase, J. C.
Green, S.
Haas, T.
Masood, A.
Gasal, E.
Ribas, A.
Schadendorf, D.
ANNALS OF ONCOLOGY, 2020, 31 : S1172 - S1172
[33] KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib (ola) vs pembro plus chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC
Saji, S.
Cussac, A. Llombart
Andre, F.
Robson, M. E.
Harbeck, N.
Schmid, P.
Cescon, D. W.
Ahn, J. S.
Nanda, R.
Fan, L.
Mejia, J. A.
Karantza, V.
Bardia, A.
Rugo, H. S.
ANNALS OF ONCOLOGY, 2020, 31 : S1268 - S1268
[34] Randomized, open-label, 3-arm phase III study comparing MK-1308A+lenvatinib and pembrolizumab (pembro) plus belzutifan plus lenvatinib versus pembro plus lenvatinib as first-line (1L) treatment for advanced clear cell renal cell carcinoma (ccRCC)
Rini, B. I.
Plimack, E. R.
Powles, T. B.
Voss, M. H.
Gurney, H. P.
Silverman, R.
Perini, R.
Rodriguez-Lopez, K.
Choueiri, T. K.
ANNALS OF ONCOLOGY, 2021, 32 : S722 - S723
[35] Preliminary findings from part 1 of COMBI-i: A phase III study of anti-PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma.
Dummer, Reinhard
Fernandez, Ana Maria Arance
Hansson, Johan
Larkin, James M. G.
Long, Georgina V.
Gasal, Eduard
Kaper, Mathilde
Upalawanna, Allison
Mookerjee, Bijoyesh
Victoria
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
[36] Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial.
Dummer, Reinhard
Long, Georgina V.
Tawbi, Hussein A.
Flaherty, Keith
Ascierto, Paolo Antonio
Nathan, Paul D.
Rutkowski, Piotr
Leonov, Oleg
Mandala, Mario
Lorigan, Paul
Ferrucci, Pier Francesco
Grob, Jean-Jacques
Meyer, Nicolas
Gogas, Helen
Stroyakovskiy, Daniil
Arance, Ana Maria
Pakhle, Neha
Waters, Sorcha
Ribas, Antoni
Schadendorf, Dirk
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[37] Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D plus T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM).
Flaherty, Keith
Daud, Adil
Weber, Jeffrey S.
Sosman, Jeffrey Alan
Kim, Kevin
Gonzalez, Rene
Hamid, Omid
Infante, Jeffrey R.
Cebon, Jonathan S.
Schuchter, Lynn Mara
Long, Georgina V.
Algazi, Alain Patrick
Kudchadkar, Ragini Reiney
Puzanov, Igor
Lawrence, Donald P.
Kline, Amy S.
Cunningham, Elizabeth Ann
Sun, Peng
Patel, Kiran
Kefford, Richard
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[38] Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) plus trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma
Robert, C.
Karaszewska, B.
Schachter, J.
Rutkowski, P.
Mackiewicz, A.
Stroyakovskiy, D.
Dummer, R.
Grange, F.
Mortier, L.
Chiarion-Sileni, V.
Drucis, K.
Krajsovÿ, I.
Hauschild, A.
Mookerjee, B.
Legos, J. J.
Zhang, Y.
Lane, S.
Schadendorf, D.
ANNALS OF ONCOLOGY, 2016, 27
[39] Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) plus trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma.
Flaherty, Keith
Davies, Michael A.
Grob, Jean Jacques
Long, Georgina V.
Nathan, Paul D.
Ribas, Antoni
Robert, Caroline
Schadendorf, Dirk
Frederick, Dennie T.
Hammond, Marc R.
Jane-Valbuena, Judit
Mu, Xinmeng Jasmine
Squires, Matthew
Jaeger, Savina A.
Lane, Stephen R.
Mookerjee, Bijoyesh
Garraway, Levi A.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[40] Randomized, placebo-controlled phase III study of 1L pembrolizumab (Pembro) plus carboplatin/taxane followed by pembro with or without maintenance olaparib in patients (Pts) with metastatic squamous non-small cell lung cancer (sqNSCLC): KEYLYNK-008
Gray, J. E.
Owonikoko, T. K.
Kato, T.
Nadal, E.
Greystoke, A.
Cardona, A. F.
Penrod, J.
Wei, Z.
Lara-Guerra, H.
Schulz, C.
ANNALS OF ONCOLOGY, 2020, 31 : S896 - S896

← 1 2 3 4 5 →